Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review.

The management of Psoriatic arthritis (PsA) has evolved in the last decade with a significant increase in treatment options making the choice for clinicians difficult. Thus, the different factors of good prognosis for each treatment are presented in this review. Current available treatment and assessment tools for the response of treatment are presented. A systematic review of the literature, on Pubmed, Medline and Cochrane databases and abstracts from the last three EULAR and ACR annual conferences was performed. Factors associated with a good response to csDMARDs, tsDMARDs and bDMARDs are presented. Dactylitis and axial involvement are associated with a poor response to methotrexate. Leflunomide has shown better efficacy in the presence of established polyarticular involvement. TNF inhibitors are to be preferred in young men with an elevated CRP while obesity, high disease activity and long disease duration are factors associated with poor response. Apremilast and ustekinumab are more effective in mono and oligo articular disease. Abatacept is more effective in patients with high CRP, high disease activity and polyarticular involvement. Finally, there are no available data with the anti IL17 These factors are some arguments to help clinicians, but comparative study are needed to conclude.

Citation

Christine Mekhail, Mickaël Chouk, Clément Prati, Daniel Wendling, Frank Verhoeven. Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. Expert review of clinical pharmacology. 2020 May;13(5):505-519

Mesh Tags

Substances

PMID: 32306777

search → result